

Cover Story
By Claire Dietz and Paul Goldberg
“If you want to see what a cure looks like, you already have,” said Tom Whitehead as his daughter Emily joined him at the lectern at the public hearing of the FDA Oncologic Drugs Advisory Committee July 12.“She's standing right beside me.”
In Brief
Drugs & Targets
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Anthony El-Khoueiry named director of USC Norris
- In the epicenter of the measles outbreak, “love thy neighbor” does not extend to vaccination rates
A dispatch from Lancaster County - NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on














